Laurence H. Belkoff
Expertise in
46
conditions

Dr. Laurence H. Belkoff

Urology
Urologic Consultants Of SE PA, LLP
231 North Broad Street, 2nd Floor, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
46
conditions
Urologic Consultants Of SE PA, LLP
231 North Broad Street, 2nd Floor, 
Philadelphia, PA 

Overview

Laurence Belkoff is a Urologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Belkoff is highly rated in 46 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Enlarged Prostate (BPH), Non-Muscle Invasive Bladder Cancer, Ureteroscopy, and Prostatectomy.

Dr. Belkoff is board certified in American Osteopathic Board Of Urological Surgery. He is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 17 clinical trials.

Specialties

Urology

Licenses

Urology in PA

Board Certifications

American Osteopathic Board Of Urological Surgery

Hospital Affiliations

Nazareth Hospital
Mercy Fitzgerald Hospital
Roxborough Memorial Hospital
Temple University Hospital
Bryn Mawr Hospital
St Luke's Hospital - Grand View Campus
Main Line Hospital Lankenau

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

Urologic Consultants of SE PA, LLP
231 North Broad Street, 2nd Floor, Philadelphia, PA 19107
Other Locations
Urologic Consultants of SE PA, LLP
1 Presidential Boulevard, Suite 100, Bala Cynwyd, PA 19004

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase II Clinical Study of Intravesical Ruvidar® in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ (CIS) or Patients Who Are Intolerant to BCG Therapy (Study II)
A Phase II Clinical Study of Intravesical Ruvidar® in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ (CIS) or Patients Who Are Intolerant to BCG Therapy (Study II)
Enrollment Status: Recruiting
Publish Date: November 24, 2025
Intervention Type: Combination product
Study Drug: TLD-1433
Study Phase: Phase 2
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2026
Intervention Type: Drug
Study Drug: UGN-102
Study Phase: Phase 3
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological
Study Drugs: Aglatimagene besadenovec, Valacyclovir
Study Phase: Phase 3
Evaluation of Applaud Medical's Acoustic Enhancer With Laser Lithotripsy System in the Treatment of Urinary Stones
Evaluation of Applaud Medical's Acoustic Enhancer With Laser Lithotripsy System in the Treatment of Urinary Stones
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Enrollment Status: Terminated
Publish Date: June 06, 2024
Intervention Type: Drug, Procedure
Study Drug: Mitomycin C
Study Phase: Phase 3
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: VERU-100
Study Phase: Phase 1/Phase 2
A Pilot Multicenter, Randomized, Double-Blind Study Comparing The Proportion Of Responders to PSD502 and to Placebo Using the PEBEQ In Subjects With Premature Ejaculation
A Pilot Multicenter, Randomized, Double-Blind Study Comparing The Proportion Of Responders to PSD502 and to Placebo Using the PEBEQ In Subjects With Premature Ejaculation
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drug: PSD502
Study Phase: Phase 2
View 9 Less Clinical Trials

43 Total Publications

Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.
Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.
Journal: The Journal of urology
Published: June 10, 2026
Similar Doctors
Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Penn Urology Perelman

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (1.8 miles away)
215-662-2891
Languages Spoken:
English
See accepted insurances

Trinity Bivalacqua is a Urologist practicing medicine in Philadelphia, Pennsylvania. Dr. Bivalacqua is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Prostatectomy.

Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required
Before you request

Penn Urology University City

3737 Market Street, 4th Floor, 
Philadelphia, PA 
 (2.1 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Phillip Pierorazio is a Urologist practicing medicine in Philadelphia, Pennsylvania. Dr. Pierorazio is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Testicular Cancer, Upper Tract Urothelial Carcinoma (UTUC), Nephrectomy, and Orchiectomy. Dr. Pierorazio is board certified in Urology, 2015. Dr. Pierorazio is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Huntingdon Pike

8 Huntingdon Pike, 
Rockledge, PA 
 (9.5 miles away)
888-369-2427
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Uzzo is a Urologist practicing medicine in Rockledge, Pennsylvania. Dr. Uzzo is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Renal Oncocytoma, Nephrectomy, and Cystectomy. Dr. Uzzo is board certified in American Board Of Urology.

Frequently Asked Questions about Dr. Laurence H. Belkoff

How do I make an appointment with Dr. Laurence H. Belkoff?

You can book an appointment with Dr. Laurence H. Belkoff by calling their office at 215-762-3200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Laurence H. Belkoff a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Laurence H. Belkoff is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Laurence H. Belkoff specialize in?

While Dr. Laurence H. Belkoff is a Urology, they have specific expertise in Prostate Cancer, Enlarged Prostate (BPH), and Non-Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Urology.

Does Dr. Laurence H. Belkoff participate in research or clinical trials?

Yes. Dr. Laurence H. Belkoff has published 43 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Laurence H. Belkoff's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Laurence H. Belkoff accept my insurance?

Dr. Laurence H. Belkoff accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 215-762-3200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Belkoff's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 34 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile